Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05751512 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Name: A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN — clinical trial record (NCT05751512)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorLepu Biopharma Co., Ltd.

Started2023-04-04

View on ClinicalTrials.gov ↗

The objective of this study is to compare the efficacy and safety of MRG003 versus cetuximab/methotrexate as second/third line of therapy in patients with RM-SCCHN who have previously failed PD-1 (L1) inhibitors and platinum-based therapy.

Trial Details

NCT Number	NCT05751512
Lead Sponsor	Lepu Biopharma Co., Ltd.
Conditions	Squamous Cell Carcinoma of the Head and Neck
Enrollment	180 participants
Start Date	2023-04-04
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-09-04